ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

RPX7009

Also written as “RPX7009 and RPX2014”, “Meropenem plus vaborbactam” and “Combination RPX7009 and RPX2014”.

Its studies are mostly in Bacterial Infections · Renal Insufficiency, led by 2 companies.

Drug pageRPX7009: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Dec 13, 20126 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only50 open or runningphase 1since Dec 13, 2012Dec 13, 2012none ahead
Menarini Group11 open or runningphase 2since Feb 3, 2025Feb 3, 2025Oct 2027phase 2 · NCT06828848

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Menarini Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 3, 2025First study: phase 2 study in Gram Negative InfectionsFirst studyNCT06828848 · 44 planned · Czechia, France, Italy and more
  2. Oct 7, 2026Primary completion moved from 2026-07 to 2027-10Date moved laterphase 2 · +15 months · NCT06828848

Ahead

  1. Oct 2027Primary completion: phase 2 study in Gram Negative InfectionsNCT06828848

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Carbepenem-hydrolyzing beta-lactamase KPC inhibitor”ChEMBL 37, by rule

Studies

The one study Menarini Group leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06828848Gram Negative Infections · Czechia, France, Italy and more2RecruitingOct 202744

How it is read

Names in the registry

  • “RPX7009”, 3 entries
  • “RPX7009 and RPX2014”, 2 entries
  • “Meropenem plus vaborbactam”, 1 entry
  • “Combination RPX7009 and RPX2014”, 1 entry

Codes read as this program: RPX7009.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.